Cat. No.: HY-139254

Indirubin-3′-oxime

(Synonyms: IDR3O; I3O)

Customer Review

Based on 1 Customer Validation

Indirubin-3′-oxime (IDR3O), a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC₅₀s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes.

For research use only. We do not sell to patients.

Purity: 99.10%
CAS No.: 667463-82-3
Formula: C₁₆H₁₁N₃O₂
Molecular Weight:277.28

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Indirubin-3′-oxime Chemical Structure

CAS No.: 667463-82-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]^[2]^[3]

JNK1

0.8 μM (IC₅₀)

JNK2

1.4 μM (IC₅₀)

JNK3

1 μM (IC₅₀)

GSK-3β

CDK

All CDK Isoforms :

All GSK-3 Isoforms :

All JNK Isoforms :

All Wnt Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	27 μM Compound: 5a	Antiproliferative activity against apoptosis resistant human A549 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis resistant human A549 cells after 72 hrs by MTT assay	[PMID: 26883150]
A549	IC₅₀	4.04 μM Compound: IO	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
A549	IC₅₀	4.17 μM Compound: IDM	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay	[PMID: 37832229]
A549	IC₅₀	5.82 μM Compound: IM	Growth inhibition of human A549 cells incubated for 3 days by SRB assay Growth inhibition of human A549 cells incubated for 3 days by SRB assay	[PMID: 28625363]
A549	IC₅₀	6.06 μM Compound: IDM	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay	[PMID: 37832229]
A549	IC₅₀	8.21 μM Compound: IDM	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
B16-F10	IC₅₀	5.4 μM Compound: 5a	Antiproliferative activity against apoptosis sensitive mouse B16F10 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 26883150]
HCT-116	IC₅₀	0.83 μM Compound: IDM	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay	[PMID: 37832229]
HCT-116	IC₅₀	1.37 μM Compound: IDM	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay	[PMID: 37832229]
HCT-116	IC₅₀	3.88 μM Compound: IDM	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
HCT-116	IC₅₀	4.22 μM Compound: IO	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
HepG2	IC₅₀	15 μM Compound: 2	Antiproliferative activity against human HepG2 cells assessed cell survival after 24 hrs by alamarBlue assay Antiproliferative activity against human HepG2 cells assessed cell survival after 24 hrs by alamarBlue assay	[PMID: 25765906]
HepG2	IC₅₀	5.66 μM Compound: IO	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
HL-60	GI₅₀	36.6 μM Compound: 18	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 3 days by trypan blue staining based inverted microscope method Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 3 days by trypan blue staining based inverted microscope method	[PMID: 34161865]
Hs 683	IC₅₀	6 μM Compound: 5a	Antiproliferative activity against apoptosis sensitive human Hs683 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive human Hs683 cells after 72 hrs by MTT assay	[PMID: 26883150]
HuCCT-1	IC₅₀	5 μM Compound: 18	Antiproliferative activity against human HuCCT-1 cells assessed as cell growth inhibition measured upto 72 hrs by CCK-8 assay Antiproliferative activity against human HuCCT-1 cells assessed as cell growth inhibition measured upto 72 hrs by CCK-8 assay	[PMID: 34161865]
HUVEC	IC₅₀	0.36 μM Compound: 18	Antiproliferative activity against HUVEC cells assessed as cell growth inhibition measured after 3 days by [3H]-thymidine incorporation assay Antiproliferative activity against HUVEC cells assessed as cell growth inhibition measured after 3 days by [3H]-thymidine incorporation assay	[PMID: 34161865]
KB	IC₅₀	5.34 μM Compound: IM	Growth inhibition of human KB cells incubated for 3 days by SRB assay Growth inhibition of human KB cells incubated for 3 days by SRB assay	[PMID: 28625363]
LoVo	IC₅₀	8.9 μM Compound: 5a	Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay	[PMID: 26883150]
LXFL 529	IC₅₀	3 μM Compound: 18	Cytotoxicity against human LXFL 529 cells assessed as cell growth inhibition measured after 3 days by SRB assay Cytotoxicity against human LXFL 529 cells assessed as cell growth inhibition measured after 3 days by SRB assay	[PMID: 34161865]
MCF7	IC₅₀	1.41 μM Compound: IDM	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay	[PMID: 37832229]
MCF7	IC₅₀	2.33 μM Compound: IDM	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay	[PMID: 37832229]
MCF7	IC₅₀	3.3 μM Compound: 18	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 3 days by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 3 days by SRB assay	[PMID: 34161865]
MCF7	IC₅₀	4.1 μM Compound: IDM	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
MCF7	IC₅₀	6.81 μM Compound: IM	Growth inhibition of human MCF7 cells incubated for 3 days by SRB assay Growth inhibition of human MCF7 cells incubated for 3 days by SRB assay	[PMID: 28625363]
MCF7	IC₅₀	9.2 μM Compound: 5a	Antiproliferative activity against apoptosis sensitive human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive human MCF7 cells after 72 hrs by MTT assay	[PMID: 26883150]
MDA-MB-231	IC₅₀	5.16 μM Compound: IO	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
MDA-MB-231	IC₅₀	7.59 μM Compound: IM	Growth inhibition of human MDA-MB-231 cells incubated for 3 days by SRB assay Growth inhibition of human MDA-MB-231 cells incubated for 3 days by SRB assay	[PMID: 28625363]
MV4-11	IC₅₀	1.69 μM Compound: IDM	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay	[PMID: 37832229]
MV4-11	IC₅₀	2.36 μM Compound: IDM	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay	[PMID: 37832229]
MV4-11	IC₅₀	30 nM Compound: 18	Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured after 72 hrs by tetrazolium staining based WST-8 assay Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured after 72 hrs by tetrazolium staining based WST-8 assay	[PMID: 34161865]
MV4-11	IC₅₀	6.01 μM Compound: IDM	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
NCI-H23	IC₅₀	11.25 μM Compound: Indirubin-3'-oxime	Cytotoxicity against human NCI-H23 cells by colorimetric method Cytotoxicity against human NCI-H23 cells by colorimetric method	[PMID: 32916298]
NCM460	IC₅₀	13.13 μM Compound: IDM	Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
NCM460	IC₅₀	20.18 μM Compound: IDM	Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay	[PMID: 37832229]
NCM460	IC₅₀	21.13 μM Compound: IDM	Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay	[PMID: 37832229]
Oocyte	IC₅₀	0.18 μM Compound: 18	Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis	[PMID: 34161865]
PC-3	IC₅₀	15.8 μM Compound: Indirubin-3'-oxime	Cytotoxicity against human PC3 cells by colorimetric method Cytotoxicity against human PC3 cells by colorimetric method	[PMID: 32916298]
PC-3	IC₅₀	24.3 μM Compound: 5a	Antiproliferative activity against apoptosis sensitive human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive human PC3 cells after 72 hrs by MTT assay	[PMID: 26883150]
SK-MEL-28	IC₅₀	26.6 μM Compound: 5a	Antiproliferative activity against apoptosis resistant human SK-MEL-28 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis resistant human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 26883150]
SW-620	IC₅₀	13.5 μM Compound: Indirubin-3'-oxime	Cytotoxicity against human SW620 cells by colorimetric method Cytotoxicity against human SW620 cells by colorimetric method	[PMID: 32916298]
U-373MG ATCC	IC₅₀	18 μM Compound: 5a	Antiproliferative activity against apoptosis resistant human U373 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis resistant human U373 cells after 72 hrs by MTT assay	[PMID: 26883150]

In Vitro

In cerebellar granule neurons (CGNs), Indirubin-3′-oxime blocks c-Jun phosphorylation induced by potassium withdrawal and prevented CGNs from apoptosis in a dose dependent manner^[1].
Indirubin-3′-oxime (IDR3O) (PC12 cells; 10 μM) significantly prevent 6OHDA-induced decrease of nuclear localized MEF2D expression^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Indirubin-3′-oxime (0.05 or 0.5 mg/kg; i.p.; daily for 2 or 10 weeks) enhances tibial longitudinal growth in mice without adverse changes in bone thickness parameters^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Three-week-old C57BL/6 mice^[3]
Dosage:

0.05 or 0.5 mg/kg
Administration:

I.p.; daily for 2 or 10 weeks
Result:

The tibial length of mice increased in a dose-dependent manner.

Chemical Information

CAS No. 667463-82-3
Appearance Solid
Molecular Weight 277.28
Formula C₁₆H₁₁N₃O₂
Color Brown to red
SMILES

O/N=C1C2=C(C=CC=C2)NC\1=C3C4=C(C=CC=C4)NC\3=O
Synonyms

IDR3O; I3O
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (360.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.6065 mL

18.0323 mL

36.0646 mL

5 mM

0.7213 mL

3.6065 mL

7.2129 mL

10 mM

0.3606 mL

1.8032 mL

3.6065 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (604 KB)
- English - EN (604 KB)
- Français - FR (604 KB)
- Deutsch - DE (604 KB)
- Norwegian - NO (604 KB)
- Español - ES (604 KB)
- Swedish - SV (604 KB)
- Italian - IT (604 KB)
- Korean - KR (604 KB)
- Portuguese - PT (604 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Xie Y, et al. Indirubin-3'-oxime inhibits c-Jun NH2-terminal kinase: anti-apoptotic effect in cerebellar granule neurons. Neurosci Lett. 2004;367(3):355-359. [Content Brief]

[2]. Hu S, et al. Indirubin-3-Oxime Effectively Prevents 6OHDA-Induced Neurotoxicity in PC12 Cells via Activating MEF2D Through the Inhibition of GSK3β. J Mol Neurosci. 2015;57(4):561-570. [Content Brief]

[3]. Choi S, et al. Indirubin-3'-oxime stimulates chondrocyte maturation and longitudinal bone growth via activation of the Wnt/β-catenin pathway. Exp Mol Med. 2019;51(9):1-10. Published 2019 Sep 12. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.6065 mL	18.0323 mL	36.0646 mL	90.1616 mL
	5 mM	0.7213 mL	3.6065 mL	7.2129 mL	18.0323 mL
	10 mM	0.3606 mL	1.8032 mL	3.6065 mL	9.0162 mL
	15 mM	0.2404 mL	1.2022 mL	2.4043 mL	6.0108 mL
	20 mM	0.1803 mL	0.9016 mL	1.8032 mL	4.5081 mL
	25 mM	0.1443 mL	0.7213 mL	1.4426 mL	3.6065 mL
	30 mM	0.1202 mL	0.6011 mL	1.2022 mL	3.0054 mL
	40 mM	0.0902 mL	0.4508 mL	0.9016 mL	2.2540 mL
	50 mM	0.0721 mL	0.3606 mL	0.7213 mL	1.8032 mL
	60 mM	0.0601 mL	0.3005 mL	0.6011 mL	1.5027 mL
	80 mM	0.0451 mL	0.2254 mL	0.4508 mL	1.1270 mL
	100 mM	0.0361 mL	0.1803 mL	0.3606 mL	0.9016 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Indirubin-3′-oxime

Bioactive Compound Library Max

Bioactive Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Serine/Threonine Kinase Inhibitor Library

Extracellular Vesicles (EVs) Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

All CDK Isoforms

All GSK-3 Isoforms

All JNK Isoforms

All Wnt Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Indirubin-3′-oxime Related Classifications

HY-139254 Related Classifications